RxDoctor Payments Data

Jagdeep Bains, MD

Internal Medicine · Surprise, AZNPI 1013966621

Payments from drug & device makers

$1,788in general payments, 2019–2025

Across 104 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$498
  • Novo Nordisk$202
  • AbbVie$149
  • Philips North America LLC$124
  • GSK$102
  • Abbott$99
  • plus $614 from 18 others

What the payments were for

  • Food & beverage$1,788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,788 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$118,611
Medicare patients
422
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$97,155
EliquisApixaban46$73,510
MounjaroTirzepatide37$55,855
FarxigaDapagliflozin Propanediol36$49,347
JanuviaSitagliptin Phosphate20$30,869
JardianceEmpagliflozin24$29,212
RybelsusSemaglutide15$26,494
LinzessLinaclotide14$20,349
Tresiba Flextouch U-200Insulin Degludec20$19,715
XareltoRivaroxaban23$19,513
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$15,855
Repatha SyringeEvolocumab19$10,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,557
Breo ElliptaFluticasone/Vilanterol12$6,986
Losartan Potassium512$4,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$202$123,64978 claims
PfizerEliquis$81$73,51046 claims
AstraZenecaFarxiga, Breztri Aerosphere$498$65,20255 claims
Lilly USA, LLCMounjaro$43$55,85537 claims
MerckJanuvia$13$30,86920 claims
Boehringer IngelheimJardiance$87$29,21224 claims
AbbVieLinzess, Synthroid$149$22,88555 claims
Johnson & JohnsonXarelto$44$19,51323 claims
GSKTrelegy Ellipta, Breo Ellipta$102$16,54327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →